Two Onc Docs

This week dives deep into gastric adenocarcinoma, discussing risk factors like H. pylori infections and the importance of genetic testing. The latest staging techniques, including EGD and biopsies, are detailed for managing advanced cases. Advances in treatment are highlighted, with a focus on the newly approved zolbituximab for metastatic cases. The use of immunotherapy for specific genetic profiles is also explored, alongside ongoing clinical trial impacts and future directions in gastric cancer care.

Dive into a fascinating update on endometrial cancer featuring crucial insights on risk factors like Lynch syndrome. Explore the typical presentation, including postmenopausal bleeding, and learn about the diagnostic process through endometrial biopsy and FIGO staging. Discover surgical management options, adjuvant therapies, and cutting-edge molecular profiling techniques. The discussion also touches on rare uterine malignancies, providing a well-rounded overview of this critical topic.

Join oncologists Dr. Tom Powles and Dr. Brian Rini as they dive into the latest strategies for managing metastatic renal cell carcinoma. They discuss the importance of risk stratification and patient characteristics in treatment selection. The conversation covers the evolving role of cytoreductive nephrectomy, the significance of immunotherapy breaks, and the complexities of side effects from tyrosine kinase inhibitors. Listen for insights on tailored approaches for various RCC subtypes and career advice for budding oncologists!

Join renowned oncologists Tom Powles, a leading expert in GU oncology from Barts Cancer Center, and Brian Rini, a pioneer in clinical trials at Vanderbilt, as they delve into the latest insights on localized renal cell carcinoma. They explore critical risk factors, including smoking and genetic conditions like von Hippel-Lindau syndrome. The duo examines evolving treatment strategies, including nephrectomy, ablative techniques, and the emerging role of immune therapies, shedding light on their potential impacts on patient outcomes.

This discussion dives into the latest on cervical cancer, spotlighting prevention strategies and vaccination trends. They explore the critical role of HPV types 16 and 18 and highlight global disparities in screening. Management of localized cases is meticulously reviewed, featuring fertility-sparing options and radical surgery thresholds. The conversation also covers advances in treatment for locally advanced and metastatic stages, introducing new therapies and immunotherapy options. Tune in for essential insights and updates that could impact patient care.

Explore the latest on oncologic emergencies, perfect for new fellows and residents. Learn about crucial management strategies for brain metastases, including the use of dexamethasone and various radiation options. Delve into hypercalcemia treatment methods and urgent protocols for spinal cord compression. Gain insights into SVC syndrome management, emphasizing the importance of tailored therapies and timely interventions. Wrap up with high-yield takeaways that enhance your understanding of these life-threatening situations.

Delve into the groundbreaking MATTERHORN trial, where the synergy of durvalumab and the FLOT regimen offers new hope for resectable gastric cancer. Learn about the exciting results presented at the ASCO 2025 plenary session and how these findings could reshape future treatments. The discussion also explores current standards of care and the potential impact pending further research and FDA approval. This session highlights the innovative intersection of immunotherapy and conventional approaches in oncology.

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship! We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

Delve into groundbreaking advancements in breast cancer treatment with discussions on the SERENA-6 trial. The focus is on the promising combination of camisetrant and CDK 4/6 inhibitors for advanced hormone receptor-positive cases. Highlights include impressive progression-free survival improvements and the innovative use of circulating tumor DNA in managing patient care. Concerns about safety profiles and how these findings integrate into current practices add depth to the conversation.

This discussion highlights the latest updates on ovarian cancer, focusing on often-overlooked symptoms that can lead to late diagnoses. It dives into the importance of genetic testing for BRCA1-2 mutations in treatment approaches. The hosts detail treatment protocols, advocating for surgical interventions when possible, and explore the emerging maintenance therapies that show promise in improving patient outcomes. They also clarify the unique characteristics of various ovarian cancer types, reinforcing the need for personalized treatment strategies.